InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that three studies of its novel BCL2 ...

1. About LEQEMBI (generic name: lecanemab, Chinese brand name: 乐意保) ...

As the Company prepares for commercialization, RetinalGenix requires a financial, strategic, and operational leader who understands regulated medical devices, clinical development, reimbursement ...

Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles Strong efficacy data support potential advancement to earlier treatment ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, ...

CTA311 is an investigational ‘ready-at-point of care’ allogeneic anti-CD19 CAR-T cell therapy designed for B-cell mediated disease. The product candidate incorporates T-cell receptor (TCR) and HLA ...

Burixafor is an investigational small molecule that blocks CXCL12 binding to CXCR4 receptors on HPCs, rapidly mobilizing these cells from the bone marrow into the peripheral blood. In preclinical ...

The abstract can be found on the ASH Annual Meeting website, https://submit.hematology.org/program/presentation/674309 ...

Febrile infants younger than 28 days old are routinely evaluated for invasive bacterial infections such as bacterial meningitis because their early symptoms can be subtle. Most hospitals automatically ...

Irina Rabovetsky, CEO of A-Team Home Care Inc. About A-Team Home Care Inc.

CTD402’s ready-to-use manufacturing platform eliminates the 1-2 month delays inherent to autologous CAR-T therapies—delays that can be life-threatening for patients with rapidly progressive disease.

Jefferies, Leerink Partners and BofA Securities are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to ...